Accendra Health, Inc. (ACH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: while there is a focus on debt reduction and technology investments, there are concerns about inflation outpacing pricing growth and uncertainties in revenue replacement from Optum. The Q&A reveals a cautious outlook with some positive elements like expected improvements in collection rates and diversified growth in therapy categories. However, the lack of clear guidance on CapEx and the absence of a specific update on competitive dynamics temper the overall sentiment, leading to a neutral outlook.
Key Financial Performance
Revenue For all of 2025, revenue was nearly $2.8 billion, up a little more than 3%. Growth was driven by the large sleep category as well as ostomy and urology. However, a weaker collection rate compared to a strong 2024 inhibited top-line growth.
Sleep Supplies Sales Sales grew in the range of 8% to 9% for both the quarter and full year. This growth was attributed to the success of the Sleep Journey initiative.
Diabetes Category Revenue Revenue grew by almost 2% versus last year, an improvement compared to flat year-over-year results in Q3. Insulin pumps led to quarterly diabetes category growth.
Adjusted EBITDA (Q4 2025) $90 million compared to $102.5 million in last year's fourth quarter. The decline was driven by lower payment prices, inflationary product cost increases, higher health benefit costs, and stranded costs, partially offset by lower other teammate benefit costs.
Adjusted EBITDA (Full Year 2025) $375 million, up slightly from 2024. The same factors impacting Q4 results drove the full-year results.
Operating Cash Flow (Q4 2025) $68 million, which includes $67 million of cash used by the former discontinued Products & Healthcare Services business. The continuing operations business generated $135 million of cash from operating activities.
Free Cash Flow (Q4 2025) $18 million. Defined as adjusted EBITDA less patient equipment capital expenditures, net of noncash convert-to-sell write-off expense, and after consolidated interest paid.
Net Debt (End of 2025) $1.8 billion, down $315 million from September 30 and down $46 million since year-end 2024. Debt reduction was supported by $65 million paid down from ordinary free cash flow and proceeds from divestiture.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New MyApria App: Expected to launch in Q2 2026, enhancing customer experience, increasing operational efficiency, and supporting patient therapy adherence.
Sleep Journey Initiative: Continued success in the sale of sleep supplies, with growth of 8%-9% for both the quarter and full year.
Market Size: Access to approximately 300 million Americans, with 3 out of 4 adults living with chronic conditions.
Competitive Bidding Opportunities: Anticipated opportunities in diabetes, urology, and ostomy categories due to Medicare's competitive bidding process.
Technology and Automation: Leveraging technology to automate payer qualifications, improve order validation, and enhance revenue capture.
Divestiture of Products & Healthcare Services Business: Completed sale to Platinum Equity, focusing on core home-based care businesses, achieving higher margins and leaner operations.
Debt Reduction: Paid down $65 million in debt from ordinary free cash flow in Q4 2025.
Focus on Home-Based Care: Transitioned to a pure-play home-based care company post-divestiture, with a focus on stable growth, free cash flow, and debt reduction.
Capital Structure Optimization: Committed to deleveraging and optimizing capital structure to support transformation into a cash-generative business.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Loss of a large commercial payer: The company lost a significant commercial payer, which will result in a revenue impact of approximately $300 million in 2026 and an additional $40 million in 2027. This loss will significantly affect revenue growth and financial performance until the impact is fully lapped by the end of Q1 2027.
Stranded costs from divestiture: The divestiture of the Products & Healthcare Services business has left the company with stranded costs, which are now part of operating expenses. These costs are expected to impact financial performance until expense reduction measures are fully implemented.
Inflationary product cost increases: Higher costs for products due to inflation are negatively impacting the company's adjusted EBITDA and overall financial performance.
Weaker collection rates: A somewhat weaker collection rate compared to the previous year has inhibited top-line growth and could continue to pose challenges to revenue generation.
Debt levels and leverage: The company has a net debt of $1.8 billion and is focused on reducing leverage to a target of 3x adjusted EBITDA. High debt levels could constrain financial flexibility and investment capacity.
Transition costs and operational risks: The company is incurring costs related to the transition of patient care and the separation from its former parent company, Owens & Minor. These costs are expected to impact free cash flow in 2026.
Regulatory and competitive pressures: The company faces challenges related to Medicare's competitive bidding process and efforts to address fraud, waste, and abuse in the system. These factors could impact pricing and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Bullish long-term demand outlook: The company is optimistic about the long-term demand for its offerings due to economic pressures pushing care to home-based settings, an aging population with rising chronic conditions, and increasing awareness about proactive health management, particularly in the sleep category.
Competitive bidding opportunities: Accendra Health anticipates opportunities in competitive bidding for diabetes, urology, and ostomy categories, leveraging its strengths to address fraud, waste, and abuse in the system.
Technology and automation investments: The company is leveraging technology to improve customer experience and operational efficiency, including automating payer qualifications and launching the MyApria app in Q2 2026 to enhance customer experience and therapy adherence.
Revenue and EBITDA guidance for 2026: Revenue is expected to be between $2.55 billion and $2.65 billion, with adjusted EBITDA projected at $335 million to $355 million. The company anticipates a $300 million revenue impact in 2026 due to the loss of a large commercial payer, with full recovery expected by Q1 2027.
Expense reduction and cost management: The company plans to reduce expenses, including stranded costs, and has identified actions to achieve these reductions throughout 2026. This includes addressing the impact of the lost commercial payer contract.
Free cash flow expectations: Accendra Health expects at least $100 million in free cash flow for 2026, with future free cash flow projected to be comparable or better, supporting further debt reduction.
Capital structure optimization: The company is committed to deleveraging and optimizing its capital structure, with a long-term leverage target of 3x adjusted EBITDA. All net proceeds from divestitures will be used to reduce debt.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the targeted investments for RemainCo going forward?
A:The targeted investments for RemainCo in 2026 include investments in technology to lower the cost to serve and improve customer experience. There may also be opportunities for small tuck-in acquisitions, but the primary focus will be on debt reduction.
Q:How is the preferred agreement with Optum progressing?
A:The agreement is still in its early stages, and while some traction is being gained, the company acknowledges that it won't completely fill the revenue gap left by a large customer rolling off. However, it creates opportunities to redeploy resources and backfill revenue through other agreements and contract expansions.
Q:What was the patient CapEx in Q4 and how should it be viewed for 2026?
A:Patient CapEx was $45 million in Q4 and $189 million for the year. For 2026, patient CapEx is expected to run roughly 95% of the total CapEx, with guidance numbers coming down by $25-$30 million due to the loss of certain customers.
Q:Is there any update on a manufacturer re-entering the market and its potential impact?
A:There is no specific update on a manufacturer re-entering the market. However, if it happens, it could create a different competitive dynamic in the market.
Q:What is the breakdown of the adjusted EBITDA range for 2026?
A:The volume growth contributing to the adjusted EBITDA range is fairly well spread across therapy categories and customers. Preferred agreements like Optum are not the bulk of the volume growth, and the upside is distributed across various categories.
Q:Why is the company no longer guiding to a net CapEx number?
A:The company is not guiding to a net CapEx number because it does not include sales of patient CapEx. About 30% of the growth is attributed to sales of patient CapEx, and this is already included in the adjusted EBITDA number to avoid double counting.
Q:Are manufacturer cost increases and inflation outpacing pricing growth?
A:Yes, manufacturer cost increases and inflation are outpacing pricing growth. This is not linked to a specific supplier or category but is seen as an opportunity to improve EBITDA by working with manufacturing partners on pricing models and growth incentives.
Q:What are the levers for balance sheet optimization?
A:The company plans to reassess its capital structure holistically, considering the sale of the NHS business, cash on hand, and improved net debt. The focus will be on addressing debt maturities in 2027 and ensuring the capital structure fits the new business model with predictable CapEx and stronger margins.
Q:Are there broad-based cost increases across manufacturers and categories?
A:No, cost increases are not broad-based but are concentrated in major categories. These are normal inflationary trends, and the company plans to offset them through mid-year contract adjustments and collaboration with manufacturing partners.
Q:What is the confidence in improving collection rates in 2026?
A:The company is confident in improving collection rates in 2026 due to technology investments made in 2024 and 2025. These investments had a learning curve but are expected to enhance collection rates going forward.
Q:What is the current bad debt rate?
A:The company did not disclose the current bad debt rate but stated confidence in its performance compared to others in the industry.
Q:What is driving growth in the sleep category and other categories?
A:Growth in the sleep category is driven by better patient capture, recurring revenues, and an increasing number of sleep apnea diagnoses. Diabetes growth is influenced by a mix of pharmacy and DME channels. Most categories are expected to grow at low single digits, with additional initiatives planned for expansion.
Q:What are the biggest swing factors for cash flow in 2026?
A:The biggest swing factor is the $98 million transaction break fee and financing fees. The business has strong working capital dynamics and is cash generative, with opportunities for further improvement.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the current bad debt rate, stating only that they are confident in their performance compared to others in the industry.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Americans
Corporate Development
Development Investor
Form
Investor Relations
Officer Chief
President Corporate
Vice President
action
afternoon
app
belief projection
bidding
brand
capability
care home
category
condition
cost
customer experience
focus
home care
industry
market
measure
offering
patient
payer
press release
process
sale
statement
strength
technology
today
ACH Transcript
Accendra Health, Inc. (ACH) Q1 2026 Earnings Call Transcript
Unknown5-11
The earnings call reveals mixed financial performance with growth in some areas but declines in others, notably due to the exit from a large commercial payer. While the company has plans for cost management and debt reduction, uncertainties in free cash flow and reliance on older projections for future growth suggest caution. Positive elements like the Sleep Journey program and strategic initiatives are counterbalanced by challenges in diabetes and home respiratory revenue. Overall, the sentiment is balanced, leading to a neutral prediction for short-term stock price movement.
Accendra Health, Inc. (ACH) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings call presents a mixed picture: while there is a focus on debt reduction and technology investments, there are concerns about inflation outpacing pricing growth and uncertainties in revenue replacement from Optum. The Q&A reveals a cautious outlook with some positive elements like expected improvements in collection rates and diversified growth in therapy categories. However, the lack of clear guidance on CapEx and the absence of a specific update on competitive dynamics temper the overall sentiment, leading to a neutral outlook.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
